SFDA Bans Cash Transactions For Formulations Containing Controlled Substances
This article was originally published in PharmAsia News
Executive Summary
China's State FDA has issued a notice on tightening sales of formulations containing controlled substances to curb illicit extracts from formulated compounds which do not come under controlled drugs. Drug producers or distributors will be banned from cash transactions for some compound formulations, including those containing ephedrine, oral solutions containing codeine, diphenoxylate compound tablets and liquorice compound tablets. According to the notice, all companies with medicine trading licenses can operate the compound formulation business; however drug producers or distributors must file accounts information, and issue or ask for sales receipts when dealing with drugs. Wholesalers or firms that make the compound formulations directly for illegal drug producers will have their licenses revoked, and also face additional penalties. (Click here for more - Chinese Language)